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Abstract
OBJECTIVE: To observe the influence of Xinfeng-
capsule (XFC) on abarticular pathologic changes
(APCs) and other indices of patients with rheuma-
toid arthritis (RA) and explore the mechanism of ac-
tion of XFC in improving such changes.
METHODS: Three-hundred RA patients were divid-
ed randomly into a treatment group (n=150) and
control group (n=150). A normal control (NC)
group (n=90) was also created. Changes in cardiac
function, pulmonary function, anemia indices and
platelet parameters of RA patients were measured.
Curative effects of the two groups were compared,
and comparison carried out with the NC group.
RESULTS: In 300 RA patients, late diastolic peak
flow velocity (A peak) was much higher (P<0.01)
and early diastolic peak flow velocity (E peak), E/A,
and left ventricular fraction shortening much lower
(P<0.01) than those in the NC group. Vital capacity
(VC), forced vital capacity in one second, forced vi-
tal capacity (FVC), maximal voluntary ventilation
(MVV), maximal expiratory flow in 50% of VC
(FEF50) and FEF75 were lowered remarkably (P<
0.05 or P<0.01). Platelet count (PLT), plateletcrit
(PCT) and mean platelet volume (MPV) increased
markedly (P<0.05 or P<0.01), and hemoglobin (Hb)
level decreased significantly (P<0.05). After XFC
treatment, the A peak and PLT and PCT were much
lower (P<0.05), and E/A and the number of red
blood cells as well as Hb level were much higher (P<
0.05), as were FVC, MVV and FEF50 (P<0.05 or P<
0.01), in the treatment group than those in the NC
group. Total score of pain and swelling in joints,
uric-acid level and high-sensitivity C-reactive pro-
tein level were much lower, and superoxide dis-
mutase level as well as the number of CD4 +
CD25+ regulation T cells (Treg) and CD4+CD25+
CD127- Treg were much higher (P<0.05 or P<0.01)
in the treatment group than those in the NC
group.
CONCLUSION: RA patients with pathologic chang-
es in joints also suffer from lower cardiac and pul-
monary functions and from parameters of anemia
and platelet factors. XFC can improve the symp-
toms of RA patients, ameliorate their cardiac and
pulmonary functions and reduce the parameters of
anemia and platelet factors. XFC lowers the im-
mune inflammatory reaction to improve APCs in
RA patients.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease
which can cause disability and morbidity. One study
has shown that the risk of RA patients dying of cardio-
vascular disease is 2-5-times higher than that of healthy
individuals.1 RA often affects the lungs and pleura to
cause pulmonary interstitial fibrosis, bronchiectasis and
pulmonary hypertension.2 About 11% of RA patients
will suffer from secondary pulmonary interstitial patho-
logic change.3 Anemia, one of the commonest abarticu-
lar pathologic changes, is related to the activity, extent
and prognosis of RA.4 Studies have confirmed that ane-
mia within RA is characterized mainly by anemia of
chronic disease (ACD).5,6 One study discovered that,
during active RA, platelet number is enhanced, alleviat-
ed and then reduced to those seen in healthy individuals.7
In the present study, we observed changes in cardiac
function, pulmonary function, hematology and labora-
tory indices of 300 RA patients. We explored the mech-
anism of abarticular pathologic changes within RA and
studied the influence of Xinfeng capsule (XFC), a Chi-
nese drug for strengthening the spleen, removing
dampness and clearing collaterals, in subjects with RA.
MATERIALS ANDMETHODS
Ethical approval of the study protocol
The study protocol was approved by the ethics commit-
tee of the First Affiliated Hospital of Anhui University
of Traditional Chinese Medicine (Anhui Hefei, China;
2012AH-020-01). All experiments were completed at
the test center of our hospital. The center has ISO
15189 recognition (serial number of certificate, CNAS
MT0111).
Patients
The study cohort was 300 RA inpatients selected ran-
domly in the Department of Rheumatology of the
First Affiliated Hospital of Anhui University of Tradi-
tional Chinese Medicine from March 2011 to April
2013. There were 220 females and 80 males (2.75∶1)
aged 23-70 [mean, (41±15) years]. The course of ill-
ness was 0.3-35 [mean, (8 ± 4) years]. All cases con-
formed to diagnosis of RA set by the American College
of Rheumatology (revised in 1987).8
The normal (healthy volunteer) group comprised 90
patients [64 females and 26 males; 2.46∶1; mean age,
(41±13) years]. None of these individuals had obvious
organic disease as assessed by somatoscopy and immu-
nologic testing. There was no significant difference in
baseline data between the two groups (P>0.05,Table 1).
Therapy
Patients in the treatment group took three XFC cap-
sules at a time (t.d.s., p.o.; batch number, 20100116;
three-month course treatment; Drug-making Center,
First Affiliated Hospital of Anhui University of Tradi-
tional Chinese Medicine). XFC consists of Huangqi
(Radix Astragali Mongolici), Leigongteng (Radix et Rhi-
zoma Tripterygii), Yiyiren (Semen Coicis) and Wugong
(Scolopendra). Each capsule contained 0.5 g of crude
drugs.
Patients in the control group took four 2.5 mg metho-
trexate (MTX) tablets (i.e., 10 mg at a time;
three-month course treatment) once a week via the oral
route (batch number, H20100175; Shanghai Xinyi
Pharmaceutical Company Limited, Shanghai, China).
During the three-month treatment course in both
groups, patients with intolerable joint pain were also
administered non-steroid anti-inflammatory drugs. Pa-
tients with infections were given antibiotics.
Indices and methods for observations
Cardiac function: cardiac function before and after
treatment in the two groups was determined using a
VIVID®7 Ultrasound instrument (GE Healthcare, Pis-
cataway, NJ, USA) according to the method described
by Zhou et al.9
Pulmonary function: pulmonary function was deter-
mined with an Easy One Lung Function Analyzer
(Beisida, Chengdu, China) according to the method
described by Jian et al.10
Laboratory indices: various laboratory indices were de-
termined before and after treatment. Blood compo-
nents were determined using a XE-2100 Automatic
Blood Analyzer (Sysmex, Tokyo, Japan). Erythrocyte
sedimentation rate (ESR) was determined according to
the method of Wei et al.11 Levels of uric acid (UA), al-
pha-1-acid glycoprotein (α1-AGP) and high-sensitivi-
ty-C-reactive protein (hs-CRP) were determined using
a 7600 Automatic Biochemical Analyzer (Hitachi, To-
kyo, Japan). The UA kit and its reagents were pur-
chased from Wako Pure Chemical Industries (Osaka,
Japan). The hs-CRP kit was purchased from Fuxin
Changzhen Medical Science (Shanghai, China). The α
1-AGP kit was purchased from Roche Diagnostics
(Mannheim, Germany).
Regulation of T-cells: regulation of T-cells was deter-
mined in reference to the method described by Ruilian
et al.12 All reagents were purchased from Beckman
Coulter (Fullerton, CA, USA). An Epics® XL Flow Cy-
tometer (Beckman Coulter) was used.
Disease activity score (DAS)-28: the DAS-2813 is an in-
Item
Male/female
Age (years)
RA
(300 cases)
80/220
40±15
Normal control
(90 cases)
26/64
41±13
P
value
>0.05
>0.05
Table 1 Comparison of baseline data between the two
groups
533
JTCM |www. journaltcm. com October 15, 2014 |Volume 34 | Issue 5 |
Liu J et al. / Clinical Study
dex used to measure disease activity. It is calculated ac-
cording to the PREVOO method using the formula:
DAS-28=0.56 × (extracting the square root for the number of
joint tenderness)+0.28×(extracting the square root of the num-
ber of joint swelling)+0.7×In (ESR)×1.08+0.16
DAS-28 refers to the score of 28 joints: shoulders; el-
bows; wrists; finger joints of both palms; near-end in-
terphalangeal joints of both hands; and knee joints.
DAS-28>5.1 suggests disease activity. DAS-28<3.2 de-
notes low disease activity. DAS-28<2.6 suggests disease
alleviation.
Quantification of the total score of main symptoms
and signs
Quantification of the total score of the main symptoms
and signs was done in reference to Guiding Principles
for Clinical Research on New Drugs of Traditional Chi-
nese Medicine issued by the Chinese Health Ministry.14
Criteria for efficacy evaluation
The standard for evaluating curative effects was calcu-
lated in reference to Guiding Principles for Clinical Re-
search on New Drugs of Traditional Chinese Medicine
issued by the Chinese Health Ministry14 using the for-
mula:
Total effectiveness=(cases of clinical cure + cases of obvious ef-
fects+cases of effectiveness)/total cases×100%
Statistical analyses
Statistical analyses were carried out using SPSS v17.0
(IBM, New York, NY, USA). Measurement data are
the mean ± standard deviation ( xˉ ± s). The Student's
t-test was used to compare measurement data between
groups. The χ2 test was used for enumeration data.
Spearman analyses were carried out for relevant data.
P<0.05 was considered significant.
RESULTS
Changes in parameters of cardiac and pulmonary
function, anemia and platelets in 300 RA patients
Table 2 shows a comparison of changes in parameters
of cardiac and pulmonary function, anemia and plate-
let number between 300 RA patients and 90 cases in
the normal group.
Analyses of parameters of cardiac and pulmonary func-
tion, anemia indices, DAS-28, total score of symptoms
and signs, and laboratory indices of 300 RA patients
Table 3 shows analyses of parameters of cardiac and
pulmonary function, anemia indices, DAS-28, total
score of symptoms and signs, and laboratory indices of
300 RA patients.
Parameter
Cardiac function
Pulmonary function
Anemia and platelets
E peak (m/s)
A peak (m/s)
E/A
EF (%)
FS (%)
VC
FEV1
FVC
MVV
FEF25
FEF50
FEF75
PEF
Hb (g/L)
PLT (×109/L)
PCT (%)
MPV (fL)
Control group (n=90)
1.29±0.41
0.79±0.21
1.63±0.34
68.40±6.01
41.45±5.36
92.60±15.14
97.22±11.11
96.17±8.46
86.70±17.91
75.95±21.84
82.72±14.75
83.77±15.3
84.13±24.41
116.71±13.25
169.65±90.11
0.22±0.06
10.88±1.23
Treatment group (n=300)
1.01±0.28a
0.99±0.24a
1.02±0.32a
65.56±5.32
37.38±4.46a
84.74±16.93a
89.02±13.10b
82.63±12.62b
70.67±21.58a
73.33±21.36
74.69±15.42a
72.12±22.25b
76.35±24.68
102.54±18.73a
234.54±62.66b
0.29±0.04b
11.98±1.18a
Table 2 Changes in parameters of cardiac and pulmonary function, anemia, and platelets in 300 RA patients ( xˉ ±s)
Notes: patients in the treatment group took three XFC capsules at a time three times a day; patients in the control group took MTX, 10 mg
at a time, once a week, three-month course treatment. A peak: late diastolic peak flow velocity; E peak: early diastolic peak flow velocity;
EF: ejection fraction; FS: fractional shortening; VC: vital capacity; FEV1: forced vital capacity in one second; FVC: forced vital capacity;
MVV: maximal voluntary ventilation; FEF25, FEF50, FEF75: maximal expiratory flow in 25%, 50%, 75% of VC; PEF: peak expiratory
flow; Hb: hemoglobin; PLT: platelet count; PCT: plateletcrit; MPV: mean platelet volume. Compared with the datum in the Normal con-
trol group, aP<0.05, bP<0.01.
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Comparison of curative effects between the two
groups
Table 4 shows a comparison of the curative effects be-
tween the two groups. Total effectiveness in the treat-
ment group was higher than that in the control group
(χ2=6.166, P=0.013).
Curative effect of XFC on parameters of cardiac and
pulmonary function, anemia indices, parameters of
iron metabolism and parameters of platelet function in
RA patients
Table 5 shows the Curative effect of XFC on parame-
ters of cardiac and pulmonary function, anemia indi-
ces, parameters of iron metabolism and parameters of
platelet function in RA patients.
Influence of XFC on laboratory indices in RA
patients
Table 6 shows the influence of XFC on the total score
of symptoms and signs of joints, regulation of T cells,
and laboratory indices in RA patients.
Observation of adverse reactions
During treatment, no obvious adverse reactions were
noted in the treatment group. During treatment in the
MTX group, four patients with transaminase levels ex-
ceeding two-times the upper limit of normal and two
patients with obvious gastrointestinal discomfort with-
drew from clinical research. No cases dropped out
from the two groups. Therefore, eventually, there were
Group
Treatment
Control
n
150
144
Cure
5 (3.33)
5 (3.47)
Obvious effect
42 (28.00)
29 (20.14)
effectiveness
88 (58.67)
80 (55.56)
Non-effectiveness
15 (10.00)
30 (20.83)
Total effect
135 (90.00)a
114 (81.43)
Table 4 Comparison of curative effects between the two groups [n (%)]
Notes: patients in the treatment group took three XFC capsules at a time three times a day; patients in the control group tookMTX, 10 mg at a
time, once a week. aP<0.05, as compared with the datum in the control group. XFC: xinfeng capsule; MTX: methotrexate.
Parameter
Joint
symptoms
TCM
symptoms
Laboratory
indic indexes
DAS-28
Joint pain
Joint swelling
Joint
tenderness
Reduced
appetite
lassitude
Loose stool
Joint
heaviness
Local fever
IgG
IgA
IgM
RF
SOD
α1-AGP
ESR
hs-CRP
Cardiac function
E peak
﹣0.447b
0.082
﹣0.235
﹣0.108
0.389a
0.445b
0.145
﹣0.076
0.131
0.445b
0.137
0.149
0.025
0.317a
﹣0.439b
﹣0.113
﹣0.362a
EF (%)
0.103
0.083
0.086
﹣0.074
0.399a
0.447b
0.078
0.142
0.385a
0.131
0.013
0.152
﹣0.471a
0.243
﹣0.031
0.109
﹣0.173
FS (%)
0.203
0.042
﹣0.225
﹣0.017
0.112
0.155
0.147
0.152
0.192
0.303
0.131
0.019
﹣0.169
0.118
﹣0.246
0.152
﹣0.242
Pulmonary function
MVV
0.397
0.396
﹣0.328
﹣0.409
0.315
﹣0.294
﹣0.386
﹣0.389
0.312
﹣0.264
﹣0.398
﹣0.357
﹣0.387
0.163
﹣0.398
﹣0.298
﹣0.295
FEF50
﹣0.29
0.365
﹣0.429
﹣0.426
0.410
﹣0.359
﹣0.360
﹣0.420
0.375
﹣0.397
﹣0.317
﹣0.403
﹣0.387
0.348a
﹣0.420
﹣0.411
﹣0.325
PEF
﹣0.294
0.328
﹣0.376
0.420
0.310
0.396
﹣0.305
0.289
0.387
﹣0.299
﹣0.386
﹣0.358
﹣0.386
0.053
0.289
﹣0.302
﹣0.322
Anemia
Hb
content
0.029
0.040
﹣0.049
﹣0.278
0.056
0.047
﹣0.103
﹣0.172
﹣0.278
﹣0.342
﹣0.013
﹣0.191
﹣0.453a
0.142
﹣0.245
0.183
0.018
Serum
iron
0.022
0.028
﹣0.091
﹣0.171
0.045
0.139
﹣0.178
﹣0.138
﹣0.347 a
﹣0.042
﹣0.084
﹣0.172
0.207
0.417a
﹣0.037
0.082
0.063
Table 3 Analyses of parameters of cardiac and pulmonary function, anemia indices, DAS-28, total score of symptoms and signs,
and laboratory indices of 300 RA patients
Notes: E peak: early diastolic peak flow velocity; EF: ejection fraction; FS: fractional shortening; MVV: maximal voluntary ventilation;
PEF: peak expiratory flow; Hb: hemoglobin; IgG, A, M: immunoglobulin G, A, M; RF: rheumatoid factor; SOD: superoxide dismutase; α
1-AGP: alpha-1-acid glycoprotein; ESR: erythrocyte sedimentation rate; hs-CRP: high-sensitivity C-reactive protein; DAS: disease activity
score; TCM: Traditional Chinese Medicine; FEF50: maximal expiratory flow in 50% of VC. aP<0.05, bP<0.01.
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150 cases in the treatment group and 144 cases in the
control group.
DISCUSSION
We investigated the curative effect of XFC on RA. We
noted no obvious adverse reactions in the treatment
group. During treatment in the MTX group, four pa-
tients with transaminase levels exceeding two-times the
upper limit of normal and two patients with obvious
gastrointestinal discomfort withdrew from clinical re-
search. No cases dropped out from the two groups.
The prevalence of total effectiveness in the treatment
group was 90%, much higher than that in the control
group (79%) (P<0.05), suggesting that XFC has a cura-
tive effect and safe as RA treatment.
In terms of parameters of cardiac function, RA patients
had much lower early diastolic peak flow velocity (E)/
late diastolic peak flow velocity (A) and left ventricular
fractional shortening (FS) values (P<0.01), much high-
er A peaks (P<0.01) and much lower E peaks (P<0.01)
than the 90 cases in the normal control group. These
results are similar to those of other studies.15 We found
that the early stage of pathologic change in the cardiac
function of RA patients was manifested in reduced dia-
stolic function and no obvious symptoms. After treat-
ment, the A peak decreased obviously (P<0.05 or P<
0.01) and E/A increased noticeably (P<0.05 or P<
0.01) in both groups. Ejection fraction (EF) was in-
creased remarkably in the treatment group (P<0.05).
The A peak was much lower (P<0.05) and E/A much
higher (P<0.05) in the treatment group than those in
the control group, suggesting that XFC can improve
the parameters of cardiac function in RA patients mark-
edly. Spearman analyses showed that, in RA patients,
the E peak was obviously in a positive relationship
with levels of superoxide dismutase (SOD) and immu-
Notes: patients in the treatment group took three XFC capsules at a time three times a day; patients in the control group tookMTX, 10 mg at
a time, once a week, three-month course treatment. A peak: late diastolic peak flow velocity; E peak: early diastolic peak flow velocity; EF:
ejection fraction; FS: fractional shortening; VC: vital capacity; FEV1: forced vital capacity in one second; FVC: forced vital capacity; MVV:
maximal voluntary ventilation; FEF25: maximal expiratory flow in 50% of VC; PEF: peak expiratory flow; Hb: hemoglobin; RBC: red
blood cell; SF: serum ferritin; Tf: transferrin; PLT: platelet count; PCT: plateletcrit; MPV: mean platelet volume. aP<0.05, bP<0.01, as com-
pared with the datum before treatment in the same group; cP<0.05, dP<0.01, as compared with the datum after treatment in the control
group.
Parameter
Cardiac function
Pulmonary function
Anemia and iron
metabolism
Platelets
E peak (m/s)
A peak (m/s)
E /A
EF (%)
FS (%)
VC
FEV1
FVC
MVV
FEF25
FEF50
FEF75
PEF
RBC (×1012/L）
Hb (g/L)
SF (ng/L)
Tf (g/L)
PLT (×109/L)
PCT (%)
MPV (fL)
Control (n=144)
Before treatment
0.97±0.27
0.96±0.28
1.06±0.62
67.23±5.97
40.33±12.75
85.14±14.82
86.81±12.52
83.24±11.46
72.43±18.72
81.11±18.90
74.84±16.38
71.44±21.23
81.13±18.49
3.82±0.27
99.62±11.10
144.77±83.89
1.66±0.74
242.05±62.95
0.28±0.48
13.86±1.30
After treatment
1.03±0.22
0.78±0.24a
1.32±0.50a
70.00±2.78
41.21±9.43
89.13±13.42
94.58±13.83a
86.33±13.14
77.16±19.24
83.73±16.48
76.01±14.93
83.41±18.70a
83.62±17.13
3.71±0.43
114.10±18.90
152.21±113.89
1.82±0.51
223.65±83.17
0.31±0.15
11.70±1.38
Treatment (n=150)
Before treatment
0.89±0.27
0.99±0.29
0.90±0.39
65.89±5.74
39.92±4.72
84.92±11.83
84.50±14.62
84.21±13.34
75.38±18.71
80.16±20.19
73.33±16.52
72.31±21.17
77.43±21.26
3.56±0.42
88.62±13.10
118.95±82.16
1.65±0.62
241.58±58.89
0.39±0.14
11.83±0.99
After treatment
1.08±0.21a
0.64±0.22bc
1.69±0.05bc
70.89±4.01a
41.32±8.69
91.83±14.22a
96.98±13.40b
96.23±10.30bd
85.64±19.56ac
84.29±22.51
83.62±13.96ad
83.83±16.65b
83.31±19.86
3.91±0.53ac
112.10±14.90ac
152.73±134.51a
1.97±0.62a
199.93±23.86ac
0.25±0.07ac
12.29±5.77
Table 5 Curative effect of XFC on parameters of cardiac and pulmonary functions, anemia indices, parameters of iron metabolism
and parameters of platelet in RA patients ( xˉ ±s)
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noglobulin (Ig)G (P<0.01) and in negative relationship
with DAS-28 as well as levels of α1-AGP and hs-CRP
(P<0.05 or P<0.01). DAS-28 is related to cardiac dam-
age in RA patients and is a comprehensive index for
evaluating RA.16 We found that the E peaks of RA pa-
tients were obviously in a negative relationship with
DAS-28 (P<0.01), suggesting that cardiac damage in
RA patients is closely related to disease activity.
Determination of the pulmonary function of 300 RA
patients revealed the most severe pathologic changes to
take place in forced expiratory flow at 50% of forced vi-
tal capacity (FEF50), followed by FEF25 and FEF75,
and then followed by vital capacity (VC), expiratory re-
serve volume (ERV), peak expiratory flow (PEF) and
maximum voluntary ventilation (MVV). After XFC
treatment, inspiratory capacity (IC), MVV, forced vital
capacity (FVC), forced expired volume in one second
(FEV1), FEV1/FVC, FEF25, FEF50, FEF75 and PEF
of RA patients were improved. The reduction in pul-
monary function was manifested in decline of ventila-
tion and diffusion. Improvement of FVC, MVV and
FEF50 in the treatment group was much greater than
that in the control group (P<0.05 or P<0.01). FEF50
of RA patients was obviously in a positive relationship
with SOD level (P<0.05), suggesting that the pulmo-
nary function of RA patients was closely related to
pulmonary blood vessels and oxidation in pulmonary
alveoli.
Analyses of blood and iron metabolism showed that
300 RA patients had much higher platelet count
(PLT), plateletcrit (PCT) and mean platelet volume
(MPV) (P<0.05 or P<0.01) and much lower hemoglo-
bin (Hb) level (P<0.05) than 90 cases in the normal
control group. After XFC treatment, anemia indices
[number of red blood cells (RBCs) and Hb level] and
parameters of iron metabolism serum ferritin (SF),
transferrin (Tf ) and mean corpuscular volume (MCV)
increased obviously (P<0.05) and PLT and PCT de-
clined noticeably (P<0.05). Hb content was negatively
related to local fever and rheumatoid factor (RF) of
joints, and positively related to SOD level (P<0.05).
Studies have discovered that, at the active stage of RA,
PLT and PCT increase obviously and are related to the
active indices P-selective element, ESR and hs-CRP.17,18
After treatment of RA patients with XFC, the super-
microscopic structure of platelets was improved, and
expression of PLT and P-selective element was re-
duced.
We found that after XFC treatment in RA patients,
pain, swelling and morning-rigidity of joints was im-
proved. After treatment in the two groups, UA level,
hs-CRP level and ESR were reduced obviously and
SOD level as well as the number of CD4+CD25+Treg
cells and CD4+CD25+CD127- Treg cells was notice-
ably enhanced (P<0.05 or P<0.01). However, the XFC
group was superior to the MTX group in reducing lev-
els of UA and hs-CRP and enhancing SOD levels as
well as the number of CD4 + CD25 + Treg cells and
CD4+CD25+CD127- Treg cells (P<0.05 or P<0.01).
UA takes part in the generation and development of
coronary atherosclerosis of elderly female patients, and
levels of UA in patients with coronary heart disease in-
crease.19 We found that the UA levels of RA patients
was enhanced obviously (P<0.05). Hyperuricemia, like
Parameter
Total score of joint pain
Total score of joint swelling
Total score of joint tenderness
Total score of joint rigidity in the morning
IgG (g/L)
IgA (g/L)
RF (U/mL)
ESR (mm/h)
hs-CRP (mg/L)
UA (µmol/L)
SOD (U/mL)
CD4+CD25+ (%)
CD4+CD25+CD127- (%)
Control (n=144)
Before treatment
5.8±2.3
4.6±3.2
5.1±2.2
2.7±2.9
17.8±5.6
3.0±1.7
153.4±36.5
47.2±24.6
42.1±13.2
254.4±56.7
112.5±38.5
4.96±2.67
4.23±1.34
After treatment
2.9±0.6a
3.0±1.1b
2.7±1.8a
1.1±1.2b
15.1±4.5b
2.6±1.7
146.0±33.2
25.2±20.5a
25.2±13.4b
243.0±43.2b
144.4±44.9b
5.6±2.5
4.8±1.3b
Treatment (n=150)
Before treatment
5.5±2.1
4.5±2.8
4.9±2.0
2.4±3.0
18.0±6.4
2.9±1.3
165.1±42.0
51.6±21.4
48.7±15.7
305.0±84.0
108.5±31.1
4.3±2.2
4.1±1.0
After treatment
2.1±0.6ac
2.1±1.1ac
2.2±1.6a
1.2±1.1a
13.2±5.6a
2.7±1.4
147.3±38.4
24.1±18.9a
17.2±11.7ac
212.5±39.5ac
148.7±33.0a
5.7±2.9a
5.3±1.3a
Notes: patients in the treatment group took three XFC capsules at a time three times a day; patients in the control group took MTX, 10 mg
at a time, once a week, three-month course treatment. aP<0.01, bP<0.05, as compared with the datum before treatment in the same group; cP<
0.05, as compared with the datum after treatment in the control group. IgG, A: immunoglobulin G, A; RF: rheumatoid factor; ESR: erythro-
cyte sedimentation rate; hs-CRP: high-sensitivity C-reactive protein; SOD: superoxide dismutase; UA: uric acid.
Table 6 Influence of XFC on laboratory indices of RA patients ( xˉ ±s)
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hyperglycemia, hyperlipemia and hypertension, is a
dangerous risk factor for cardiovascular disease, and
our results are similar to those in other studies.14
Mild RA affects only the joints and muscles of the four
limbs, whereas severe RA can affect internal organs.
Lingering arthralgia syndrome can affect the heart,
lungs and blood vessels. In terms of traditional Chinese
medicine (TCM), the pathogenesis of lingering arthral-
gia syndrome lies in: a feeble spleen and stomach; inter-
nal dampness and turbidity; deficient Qi and blood;
imbalance between Ying and Wei; stagnation of phlegm
and stasis in the collaterals.20 TCM syndromes and
signs are characterized by spleen deficiency, exuberant
dampness and deficiency complicated with excess.
XFC consists of Huangqi (Radix Astragali Mongolici),
Leigongteng (Radix et Rhizoma Tripterygii), Yiyiren (Se-
men Coicis) and Wugong (Scolopendra) mainly for rein-
forcing Qi and strengthening the spleen. Huangqi (Ra-
dix Astragali Mongolici), Leigongteng (Radix et Rhi-
zoma Tripterygii), Yiyiren (Semen Coicis) can regulate
immunity, protect myocardiac cells, improve pulmo-
nary damage, rectify anemia, reduce disease activity
and prevent dysfunction of immunity caused by the
immune suppression of Leigongteng (Radix et Rhizoma
Tripterygii).
We found relevant indices for abarticular pathologic
changes in RA patients to be closely related to laborato-
ry indices and symptoms. XFC used to treat RA can
obviously improve symptoms and laboratory indices,
ameliorate cardiac and pulmonary functions, effective-
ly treat anemia and improve platelet parameters, with a
total curative effect superior to that of MTX. Its mech-
anism of action lies in reduction of UA level, hs-CRP
level and ESR, enhancing SOD levels, regulating the
number of T cells, and reducing the risk of repeated re-
lapse of the immune inflammatory reaction.
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